What is the Org number of AURA BIOPHARM AS?

AURA BIOPHARM AS is registered with Brønnøysundsregistrene under Org 916837658.

Who is the chairman of AURA BIOPHARM AS?

Olav Flaten chairs the board of AURA BIOPHARM AS, in role since 2020.

Where is AURA BIOPHARM AS headquartered?

AURA BIOPHARM AS's registered address is Øvre Ullern terrasse 3C, 0380 Oslo.

AURA BIOPHARM AS

ASActive

Org 916837658Øvre Ullern terrasse 3C, 0380 OsloResearch and experimental development on natural sciences and engineering · NACE 7210Est. 20160 employees

Revenue 2024

NOK 0

EBITDA margin

—

+14% vs 2023

Equity ratio

-2177.4%

Financial strength

Net profit 2024

NOK -135K

+14% vs 2023

EBITDA — year on yearNOK millions

Key figuresAnnual report 2024

Revenue	NOK 0	—
EBITDA	NOK -135K	+14%
Net profit	NOK -135K	+14%
Total assets	NOK 41K	+42%
Equity	NOK -885K	-18%
Employees	0	—

Item	2020	2021	2022	2023	2024
Revenue	120	0	0	0	0
Staff expenses	−0	−0	−0	−0	−0
EBITDA	−158	−159	−164	−156	−135
Depreciation & amort.	−0	−0	−0	−0	−0
EBIT	−158	−159	−164	−156	−135
Net financials	−28	−1	−0	−0	−0
Profit before tax	−186	−160	−164	−157	−135
Tax	−0	−0	−0	−0	−0
Net profit	−186	−160	−164	−157	−135

Item	2020	2021	2022	2023	2024
Total assets	175	99	14	29	41
Equity	−269	−429	−593	−750	−885
Long-term debt	420	507	598	760	898
Short-term debt	24	21	8	18	28
Total debt	444	528	607	778	925

Name	Role	Member since
Current (2)
FY Francois Yves Curtin	Board of Directors	2020
OF Olav Flaten	Chairman	2020

Shareholder	Type	Ownership	Votes	Since
Minibody Sciences Inc	Company	80%	80%	2024
Hunemo As	Company	6.57%	6.57%	2024
Ferdinando Nicoletti	Individual	4.57%	4.57%	2024
Antonio Guglietta	Individual	4.45%	4.45%	2024
Francois Yves Curtin	Company	4.41%	4.41%	2024

Person	Role here	Other companies
Francois Yves Curtin	Board of Directors	0 companies
Olav Flaten	Chairman	0 companies

AURA BIOPHARM AS

ASActive

Org 916837658Øvre Ullern terrasse 3C, 0380 OsloResearch and experimental development on natural sciences and engineering · NACE 7210Est. 20160 employees

Revenue 2024

NOK 0

EBITDA margin

—

+14% vs 2023

Equity ratio

-2177.4%

Financial strength

Net profit 2024

NOK -135K

+14% vs 2023

EBITDA — year on yearNOK millions

Key figuresAnnual report 2024

Revenue	NOK 0	—
EBITDA	NOK -135K	+14%
Net profit	NOK -135K	+14%
Total assets	NOK 41K	+42%
Equity	NOK -885K	-18%
Employees	0	—